Upgrade to SI Premium - Free Trial

Biogen (BIIB) Reiterated at Buy by Stifel After Investor Meeting

September 10, 2026 7:39 AM
Stifel analyst Paul Matteis reiterated a Buy rating and $242.00 price target on Biogen (NASDAQ: BIIB).The analyst commented, "We hosted ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments